Abstract
Introduction: In this study, a series of novel piperazine derivatives were synthesised with high-to-good yields, and their structural analogies were confirmed using FTIR, 1H-NMR, and LC-MS techniques.
Methods: The synthesised compounds were evaluated for antioxidant and antimicrobial activities. Among the four synthesised piperazine derivatives, compound PD-2 exhibited relatively good antioxidant activity, with an IC50 value of 2.396 μg/mL, while the other three derivatives showed moderate to low antioxidant activity. Furthermore, compound PD-2 displayed antimicrobial activity against Pseudomonas aeruginosa, a gram-negative bacterium, and Candida albicans, a fungus. However, all four compounds showed strong resistance against grampositive bacteria, Staphylococcus aureus.
Results: Additionally, compound PD-1 exhibited significant antihistamine activity, eliciting an 18.22% reduction in histamine levels. Both PD-1 and PD-2 demonstrated noteworthy anti-inflammatory activity in a dosedependent manner (5-10 μM), leading to the inhibition of nitrite production up to 39.42% and 33.7% at higher concentrations (10 μM) and inhibition of tumour necrosis factor-alpha (TNF-α) generation up to 56.97% and 44.73% at 10 μM, respectively. Additionally, both novel molecules PD-1 and PD-2 effectively restrained the growth of HepG2 cells in a manner that is dependent on the dosage up to 55.44% and 90.45% at the highest concentrations (100 μg/mL), respectively.
Conclusion: These findings substantiate the rationale for further investigation into the novel series of persuasive piperazine analogues as potential agents with anti-inflammatory, antihistamine and anticancer properties.
Keywords: Piperazine scaffold, DPPH, antimicrobial, ZOI, cytokine ELISA, HepG2 cells.
[http://dx.doi.org/10.3329/icpj.v1i5.10284]
[http://dx.doi.org/10.3390/molecules27123698] [PMID: 35744824]
[http://dx.doi.org/10.1016/S2221-1691(12)60154-3]
[http://dx.doi.org/10.1007/s11094-022-02597-z]
[http://dx.doi.org/10.1080/14756366.2021.1931861] [PMID: 34080510]
[http://dx.doi.org/10.1155/1999/378394] [PMID: 22346384]
[http://dx.doi.org/10.22159/ijap.2020v12i5.38586]
[http://dx.doi.org/10.1124/mol.61.2.391] [PMID: 11809864]
[http://dx.doi.org/10.31788/RJC.2023.1618114]
[http://dx.doi.org/10.1016/j.pbb.2015.05.021] [PMID: 26047769]
[http://dx.doi.org/10.22159/ijap.2023v15i4.45811]
[http://dx.doi.org/10.1002/cssc.201501367] [PMID: 26663906]
[http://dx.doi.org/10.13040/IJPSR.0975-8232.6(10).4145-58]
[http://dx.doi.org/10.2147/LRA.S6453] [PMID: 22915870]
[http://dx.doi.org/10.3390/ijms22073380] [PMID: 33806141]
[http://dx.doi.org/10.2174/1573407219666230511150434]
[http://dx.doi.org/10.1016/S0076-6879(99)99005-5] [PMID: 9916193]
[http://dx.doi.org/10.2147/IJN.S193192] [PMID: 31190806]
[http://dx.doi.org/10.31925/farmacia.2023.1.16]
[http://dx.doi.org/10.7324/JAPS.2023.58094]
[http://dx.doi.org/10.1016/S0091-6749(05)80188-5] [PMID: 2229845]
[http://dx.doi.org/10.3389/fphys.2021.735247] [PMID: 34650445]
[http://dx.doi.org/10.1016/j.molstruc.2021.131020] [PMID: 34248201]
[http://dx.doi.org/10.1155/2011/291720]
[http://dx.doi.org/10.1016/j.ijid.2003.03.002] [PMID: 14690779]
[http://dx.doi.org/10.1016/j.bmcl.2012.08.071] [PMID: 22981334]
[http://dx.doi.org/10.1021/ac50045a032]
[http://dx.doi.org/10.3892/ol.2016.5288] [PMID: 28105167]
![Wayfinder Image](/images/wayfinder.jpg)